The integration of artificial intelligence into the healthcare system, particularly in the complex realm of insurance prior authorization, is a development fraught with both promise and peril. While proponents champion AI’s potential to streamline processes, reduce administrative burdens, and theoretically expedite approvals for medically necessary treatments, a growing chorus of physicians, patient advocates, and policymakers express deep concerns about its potential to exacerbate existing inequities and lead to more wrongful denials of care. As the U.S. government pilots AI-driven programs aimed at controlling healthcare costs, the fundamental question remains: will this technological advancement truly fix a broken system, or will it simply automate and amplify its inherent flaws?
The Prior Authorization Conundrum: A System Under Strain
For countless individuals, the journey to receive recommended medical care is a labyrinthine process, often entangled with the requirement of prior authorization. This administrative hurdle, mandated by health insurers, necessitates physician pre-approval for a wide range of services, from prescription medications and diagnostic tests to surgical procedures and hospital stays. While theoretically designed to curb unnecessary spending and prevent the overuse of costly treatments when less expensive alternatives exist, the reality for many patients and physicians is one of significant frustration and potentially dangerous delays.
Personal anecdotes abound regarding the arduous struggles patients face in navigating prior authorization. Physicians, who bear the brunt of this administrative burden, report spending countless hours on paperwork, phone calls, and appeals, diverting valuable time away from patient care. A significant majority of physicians, according to surveys by the American Medical Association (AMA), voice grave concerns about the impact of prior authorization on patient care. These concerns often stem from the prolonged waiting periods patients endure for approval, during which they may be forced to abandon recommended treatments altogether. The appeal process, while a recourse for denied care, introduces further delays and administrative complexity.
The Promise and Peril of AI in Prior Authorization
Artificial intelligence, with its unparalleled capacity to process vast datasets and identify patterns, is being heralded as a potential solution to the inefficiencies plaguing prior authorization. The theoretical application of AI in this domain centers on its ability to rapidly review and approve "unambiguously allowable claims," thereby freeing up human reviewers for more complex cases and, crucially, reducing delays for patients awaiting necessary treatments. The hope is that AI can act as an intelligent filter, swiftly greenlighting clear-cut cases and flagging only those that genuinely require nuanced clinical review.
However, this optimistic outlook is tempered by significant apprehension. The very efficiency that makes AI attractive also raises fears of its potential misuse. Critics worry that AI-driven prior authorization could lead to an increase in wrongful denials of health insurance coverage. A 2025 survey conducted by the AMA revealed that a substantial 61% of physicians are concerned that AI will exacerbate the denial of treatments they deem medically necessary. This apprehension is rooted in the concern that AI algorithms, if not meticulously designed and overseen, could prioritize cost savings over patient well-being, potentially misinterpreting clinical data or lacking the empathy and nuanced understanding that a human clinician brings to the decision-making process.
The AMA advocates for greater transparency in AI algorithms used by insurers and insists on the necessity of detailed clinical reasoning to justify any denial of coverage. This stance reflects a broader demand for accountability and a commitment to ensuring that technology serves as a tool to enhance care, not as a barrier to it. As Camm Epstein, a health policy analyst, aptly put it, "AI should be used to make appropriate care easier to approve, not necessary care easier to deny."
A Government Initiative: The WISeR Model
In an effort to tackle the escalating costs and inefficiencies within the healthcare system, the Trump administration has embarked on a significant pilot program utilizing AI to potentially reduce unnecessary medical spending. The Centers for Medicare and Medicaid Services (CMS) has launched the Wasteful and Inappropriate Service Reduction Model, or WISeR. This demonstration project, spanning six states and scheduled to run through December 2031, employs AI and machine learning alongside human clinical review to scrutinize services within original Medicare that are deemed vulnerable to overuse, fraud, and abuse. The initial focus areas include treatments such as skin and tissue substitutes, electrical nerve stimulator implants, and knee arthroscopy for osteoarthritis.
Historically, prior authorization has been a staple in Medicare Advantage plans, the privately administered alternative to traditional Medicare. However, its deployment in original Medicare has been limited. The WISeR model represents a notable shift, integrating AI into this critical decision-making process. This move, while aimed at cost containment, has ignited concerns among patient advocacy groups and healthcare reform advocates.
Examining the Data and Divergent Perspectives
The statistics surrounding prior authorization paint a stark picture of its impact. A Commonwealth Fund survey conducted in 2025 revealed that approximately one in five working-age adults with private insurance experienced a denial of physician-recommended medical care. For those subjected to prior authorization denials, 41% reported a delay in their care, and over a quarter observed a worsening of their health condition as a direct result.
In the realm of Medicare Advantage, where prior authorization is extensively utilized, insurers issued nearly 53 million prior authorization determinations in 2024 alone. Federal government reports have highlighted instances where Medicare Advantage plans have denied beneficiaries access to medically necessary services, even when those services appeared to meet coverage rules. While appeals often overturn initial denials—with Medicare Advantage plans reportedly overturning 81% of denials upon appeal in 2024—the initial denial itself can have devastating consequences for patients facing urgent health needs.
Despite these challenges, efforts are underway to reform the prior authorization process. A rule issued by the Biden administration in 2024 aimed to streamline prior authorization for government-run plans, mandating that insurers make urgent prior authorization decisions within 72 hours and non-urgent requests within seven calendar days. These timelines officially went into effect for most public sector health plans on January 1st of the current year. Concurrently, the Trump administration, in collaboration with insurers, pledged to further accelerate and simplify these processes. Private insurance companies have also committed to standardizing electronic requests by 2027 and reducing the volume of services subject to prior authorization by 2026, targeting common procedures like colonoscopies and cataract surgeries.
The Business Model of Denials and the Push for Transparency
A particularly contentious aspect of the WISeR model involves its financial structure. Vendors participating in the program are compensated based on "averted expenditures"—essentially, a share of the money saved by CMS through the denial of services. This creates a direct financial incentive for these vendors to reject care requests, raising long-standing concerns about profit motives overriding patient care. Several lawmakers have actively sought to block funding for the WISeR model, citing its potential threat to patient access.
This situation highlights a perceived duality in the Trump administration’s approach to prior authorization. While CMS expands AI’s use in original Medicare through WISeR, the agency simultaneously urges private insurers, including Medicare Advantage plans, to reduce and streamline their own prior authorization processes. CMS Administrator Mehmet Oz has issued a stern warning to insurance executives, stating that regulatory intervention will follow if the industry fails to address the prior authorization burden independently.
In response to these pressures, health plans have released data suggesting a reduction in prior authorization requests. Between June 2025 and April 2026, requests reportedly declined by 11%. However, it remains unclear whether this reduction correlates with a decrease in denial rates. Insurers have also pledged greater transparency regarding the clinical reasoning behind prior authorization decisions and have affirmed that AI or algorithms alone are not used to deny requests involving medical necessity or clinical considerations. These assurances aim to alleviate concerns about the absence of human oversight in AI-driven decisions.
The Unanswered Questions and the Path Forward
Despite these assurances, skepticism persists. Jared Dashevsky, a physician and founder of Healthcare Huddle, argues that while AI has the potential to eliminate administrative barriers and improve patient access, the current trajectory seems to be an "arms race to deny faster." He posits that instead of fixing a broken system, the focus is on automating and accelerating its inherent flaws.
The integration of AI into prior authorization is a complex undertaking with far-reaching implications. While the potential for efficiency and cost savings is undeniable, the ethical considerations and the risk of exacerbating existing disparities in healthcare access cannot be ignored. As the WISeR pilot program unfolds and as AI technologies become more sophisticated, ongoing scrutiny, robust oversight, and a commitment to patient-centered decision-making will be paramount. The ultimate success of AI in this domain will hinge not merely on its technological capabilities, but on its ability to be deployed equitably and ethically, ensuring that the pursuit of efficiency does not come at the expense of essential medical care. The journey to fix prior authorization is far from over, and the role of AI in this critical endeavor remains a subject of intense debate and vital importance.
